Zobrazeno 1 - 10
of 69
pro vyhledávání: '"F. Biffoni"'
Publikováno v:
Blood Cells, Molecules, and Diseases. 38:83-92
A selective lysis of relatively young erythrocytes (neocytolysis), together with a decrease of erythropoietin (EPO) production, has been described in polycythemic, high altitude acclimatized climbers, after descent to sea level, and in astronauts, so
Autor:
E. Toniutti, W. Malangone, Angela Risso, F. Biffoni, Cristina Rinaldi, L. Marini, S. Crini, G. Del Frate, Marco Pittino, E. Falasca, V Adami, A. Degrassi, E. Passoni Ferraro
Publikováno v:
Blood Cells, Molecules, and Diseases. 35:389-397
Umbilical cord blood (UCB) is a source of hematopoietic progenitor cells and is used as an alternative to the bone marrow or peripheral blood for treatment of several onco-hematological diseases. Because of the limited number of CD34+ hematopoietic s
Autor:
G. Astori, E Falasca, Laura Dorotea, W. Malangone, Corrado Pipan, F. Biffoni, A. Degrassi, L. Marini, C. Rinaldi, V Adami
Publikováno v:
Clinical Microbiology and Infection. 10:1075-1080
This report describes the development of a one-tube multiplex reverse transcriptase (RT)-PCR assay for the simultaneous detection of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in plasma samples. The assay was evaluated with two pa
Autor:
Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Mattia G, Carè A. PLoS One. 2013, 8(2):e56824. doi: 10.1371/journal.pone.0056824. Epub 2013 Feb 21. PMID: 23437250 [PubMed - in process]
Publikováno v:
PloS one 8 (2013): E56824. doi:10.1371/journal.pone.0056824.
info:cnr-pdr/source/autori:Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Mattia G, Carè A. PLoS One. 2013;8(2):e56824. doi: 10.1371%2Fjournal.pone.0056824. Epub 2013 Feb 21. PMID: 23437250 [PubMed-in process]/titolo:miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma./doi:10.1371%2Fjournal.pone.0056824./rivista:PloS one/anno:2013/pagina_da:E56824/pagina_a:/intervallo_pagine:E56824/volume:8
info:cnr-pdr/source/autori:Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Mattia G, Carè A. PLoS One. 2013;8(2):e56824. doi: 10.1371%2Fjournal.pone.0056824. Epub 2013 Feb 21. PMID: 23437250 [PubMed-in process]/titolo:miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma./doi:10.1371%2Fjournal.pone.0056824./rivista:PloS one/anno:2013/pagina_da:E56824/pagina_a:/intervallo_pagine:E56824/volume:8
The abnormal expression of several microRNAs has a causal role in tumorigenesis with either antineoplastic or oncogenic functions. Here we demonstrated that miR-126 and miR-126* play a tumor suppressor role in human melanoma through the direct or ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=cnr_________::c208bd9d836523105f13fd338b73fd55
Autor:
A. Degrassi, V Adami, Giovanni Del Frate, Luisa Marini, F. Biffoni, Pierguido Sala, Cristina Rinaldi, Elio Tonutti, Elisabetta Falasca, Riccardo Spizzo, Marco Pittino, W. Malangone, Laura Dorotea, Giuseppe Astori, Leonardo Bigi, Angela Risso
To obtain long-term engraftment and hematopoiesis in myeloablated patients, the cell population used for hematopoietic reconstitution should include a sufficient number of early pluripotent hematopoietic stem cells (HSCs), along with committed cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d738fc0642f089d36ccd58ca0f622fd9
http://hdl.handle.net/11390/877030
http://hdl.handle.net/11390/877030
Autor:
Ornella Belvedere, Cristina Rinaldi, Laura Dorotea, Elio Tonutti, F. Biffoni, Riccardo Spizzo, Dino De Anna, E Falasca, V Adami, W. Malangone, Pierguido Sala, Cristina Feruglio, G. Del Frate, G. Astori, A. Degrassi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::824866d6ae6b90b9bfc8536fc85b0a90
http://hdl.handle.net/11390/883736
http://hdl.handle.net/11390/883736
Publikováno v:
Recenti progressi in medicina. 89(2)
Among lymphomas, treatment of Hodgkin's disease (HD) allows the highest cure-rate. Radiotherapy (RT) represents first choice therapy in early stages, providing complete remission (CR) rate even superior to 90%. Chemotherapy (CHT) or, when indicated,
Autor:
C, Rinaldi, C, Savignano, F, Silvestri, A, Geromin, M, Cerno, R, Fanin, F, Biffoni, M, Baccarani
Publikováno v:
Haematologica. 80(5)
We retrospectively analyzed the factors influencing the mononuclear cell (MNC) yield on bone marrow (BM) harvests in a cohort of 15 non-Hodgkin's lymphoma patients undergoing autologous bone marrow transplantation. All the patients were treated with
Autor:
G. Fanetti, G. De Stasio, E. Mannella, Cristina Galli, A. R. Zanetti, S. De Virgiliis, Gianguglielmo Zehender, F. Biffoni, G. Marinucci, G. Ongaro, J.D. Burczak, Me Lai, H. Lee
Publikováno v:
Clinical and diagnostic virology. 2(3)
Background: Several studies carried out in the USA and in Europe have shown the presence of HTLV-I/II antibodies in subjects belonging to high-risk groups for HIV infection as well as blood donors. Concern about the presence of HTLV-I/II markers in t